Trials / Completed
CompletedNCT00415805
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
A Pilot, Open-label, Multicenter Intra-individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative and designed to provide preliminary information for consideration for a future larger study, sample size is not based on statistical assumptions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Multihance | 0.5 Molar, single injection at 0.2 mL/kg |
| DRUG | vasovist | 0.25 molar single injection 0.03 ml/kg |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-12-01
- Completion
- 2009-02-01
- First posted
- 2006-12-25
- Last updated
- 2023-08-01
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00415805. Inclusion in this directory is not an endorsement.